Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation

Jose P. Lopez-Lopez, Patricio Lopez-Jaramillo

Producción científica: Artículos / NotasComentario/Debate

Resumen

The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.

Idioma originalInglés
Páginas (desde-hasta)1461-1462
Número de páginas2
PublicaciónMed
Volumen5
N.º12
DOI
EstadoPublicada - 13 dic. 2024
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation'. En conjunto forman una huella única.

Citar esto